MinichMacGregor Wealth Management LLC Buys New Position in iShares Biotechnology ETF (NASDAQ:IBB)

MinichMacGregor Wealth Management LLC purchased a new position in shares of iShares Biotechnology ETF (NASDAQ:IBB) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,519 shares of the financial services provider’s stock, valued at approximately $221,000.

Several other hedge funds also recently made changes to their positions in IBB. Highline Wealth Partners LLC acquired a new position in iShares Biotechnology ETF during the third quarter valued at approximately $30,000. Bbjs Financial Advisors LLC acquired a new stake in shares of iShares Biotechnology ETF in the 2nd quarter valued at approximately $31,000. Voisard Asset Management Group Inc. bought a new position in shares of iShares Biotechnology ETF in the third quarter valued at $59,000. Chris Bulman Inc acquired a new position in iShares Biotechnology ETF during the second quarter worth $64,000. Finally, Eastern Bank acquired a new position in shares of iShares Biotechnology ETF during the 3rd quarter worth about $65,000. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Price Performance

NASDAQ:IBB traded down $0.09 on Tuesday, hitting $142.76. The company’s stock had a trading volume of 118,299 shares, compared to its average volume of 1,440,944. iShares Biotechnology ETF has a one year low of $113.56 and a one year high of $150.57. The stock has a fifty day moving average of $144.92 and a two-hundred day moving average of $140.69.

iShares Biotechnology ETF Dividend Announcement

The firm also recently declared a dividend, which was paid on Monday, September 30th. Investors of record on Wednesday, September 25th were paid a $0.2005 dividend. The ex-dividend date was Wednesday, September 25th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.